Humoral Immune Response to Messenger RNA COVID-19 Vaccines Among Patients With Inflammatory Bowel Disease

Gastroenterology. 2021 Oct;161(4):1340-1343.e2. doi: 10.1053/j.gastro.2021.06.016. Epub 2021 Jun 15.
No abstract available

Publication types

  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • 2019-nCoV Vaccine mRNA-1273
  • Adrenal Cortex Hormones / therapeutic use
  • Adult
  • Aged
  • Antibodies, Viral / blood*
  • BNT162 Vaccine
  • Biological Products / therapeutic use
  • Biomarkers / blood
  • COVID-19 Vaccines / administration & dosage*
  • Female
  • Gastrointestinal Agents / adverse effects
  • Gastrointestinal Agents / therapeutic use*
  • Humans
  • Immunity, Humoral*
  • Immunocompromised Host
  • Immunogenicity, Vaccine*
  • Immunosuppressive Agents / therapeutic use
  • Inflammatory Bowel Diseases / diagnosis
  • Inflammatory Bowel Diseases / drug therapy*
  • Inflammatory Bowel Diseases / immunology
  • Male
  • Middle Aged
  • Prospective Studies
  • Treatment Outcome
  • Tumor Necrosis Factor Inhibitors / therapeutic use
  • United States
  • Vaccination*

Substances

  • Adrenal Cortex Hormones
  • Antibodies, Viral
  • Biological Products
  • Biomarkers
  • COVID-19 Vaccines
  • Gastrointestinal Agents
  • Immunosuppressive Agents
  • Tumor Necrosis Factor Inhibitors
  • 2019-nCoV Vaccine mRNA-1273
  • BNT162 Vaccine